~~<i id='4604A884DB'><strike id='4604A884DB'><tt id='4604A884DB'><pre id='4604A884DB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：entertainment 2025-09-30 11:58:15 - browse：7

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Ukraine and a new approach to mental health in war

focus

hotspot

knowledge

AvialofPfizer’snewvaccinetoprotectinfantsagainstrespiratorysyncytialvirus.CourtesyPfizerPfizer’snews

WSS

FDA panel to weigh approval of NurOwn, controversial ALS drug

Senators: Long

Drug for rare kidney disease narrowly misses mark in clinical trial

FDA panel to weigh approval of NurOwn, controversial ALS drug

Senators: Long

Ukraine and a new approach to mental health in war

focus

knowledge

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why are Kaiser Permanente staff considering a strike?

Medical leaders decry Supreme Court decision on affirmative action

Intarcia’s device

State Dept. review finds Biden bears some blame for Afghanistan failures

Lasker Awards 2023: Winners in biomedical research

United colonoscopy coverage change 'may cost lives,' doctors say

FDA panel to weigh approval of NurOwn, controversial ALS drug

At least 13 dead in Texas as scorching temps continue

CDC advisers recommend seasonal use of Pfizer RSV shot

focus

STAT Virtual Event: Putting AI to the Test

How AI helped researchers track recovery from depression

STAT Virtual Event: Putting AI to the Test

Microbiome research is starting to find links to chronic diseases

CDC advisers recommend seasonal use of Pfizer RSV shot

Lasker Awards 2023: Winners in biomedical research

hotspot

hotspot

hotspot

knowledge